Jianmin Yang

2.8k total citations · 1 hit paper
127 papers, 1.6k citations indexed

About

Jianmin Yang is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Jianmin Yang has authored 127 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 45 papers in Hematology and 26 papers in Oncology. Recurrent topics in Jianmin Yang's work include Acute Myeloid Leukemia Research (36 papers), Lymphoma Diagnosis and Treatment (22 papers) and Hematopoietic Stem Cell Transplantation (13 papers). Jianmin Yang is often cited by papers focused on Acute Myeloid Leukemia Research (36 papers), Lymphoma Diagnosis and Treatment (22 papers) and Hematopoietic Stem Cell Transplantation (13 papers). Jianmin Yang collaborates with scholars based in China, United States and United Kingdom. Jianmin Yang's co-authors include Jianmin Wang, Shenglan Gong, Shuqing Lü, Xiaoxia Hu, Hong Zhou, Deming Zhao, Xianmin Song, Weiping Zhang, Hui Cheng and Gusheng Tang and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Nature Communications.

In The Last Decade

Jianmin Yang

119 papers receiving 1.6k citations

Hit Papers

Comparative transcriptome analysis reveals differences in... 2025 2026 2025 5 10 15

Peers

Jianmin Yang
Yue Han China
Carol A. de la Motte United States
Hua Xiang China
Stanley E. D’Souza United States
Yue Han China
Jianmin Yang
Citations per year, relative to Jianmin Yang Jianmin Yang (= 1×) peers Yue Han

Countries citing papers authored by Jianmin Yang

Since Specialization
Citations

This map shows the geographic impact of Jianmin Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianmin Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianmin Yang more than expected).

Fields of papers citing papers by Jianmin Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianmin Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianmin Yang. The network helps show where Jianmin Yang may publish in the future.

Co-authorship network of co-authors of Jianmin Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Jianmin Yang. A scholar is included among the top collaborators of Jianmin Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianmin Yang. Jianmin Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Wang, Ziwei, Hui Cheng, Yan Zhang, et al.. (2024). Anti-CD4 monoclonal antibody prevents chronic graft-versus-host disease in mice by inducing immune tolerance of CD8+ T cells and alleviating thymus injury. Frontiers in Immunology. 15. 1460687–1460687. 1 indexed citations
3.
Zhang, Xun, Xin Du, Guoqiang Zhang, et al.. (2024). P1.12A.05 Aumolertinib in Treatment-Naïve EGFR-Mutant NSCLC Patients with Brain Metastases:Efficacy and Safety Data from the ARTISTRY. Journal of Thoracic Oncology. 19(10). S194–S194. 1 indexed citations
4.
Song, Zhiqiang, Yang Wang, Dongliang Zhang, et al.. (2024). Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS. International Journal of Cancer. 156(5). 1033–1042.
5.
Wang, Libing, Tao Wang, Mingyu Ye, et al.. (2024). Effect of sustained measurable residue disease negativity and post‐remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults. Cancer Medicine. 13(10). e7310–e7310. 1 indexed citations
6.
Wang, Hanlin, Xiaobei Hu, Tao Wang, et al.. (2023). Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia. Nature Communications. 14(1). 1882–1882. 2 indexed citations
7.
Zhang, Xiang, Ziwei Wang, Lixia Liu, et al.. (2023). New insights into the clinical characteristics of SETD2‐mutated acute myeloid leukaemia. British Journal of Haematology. 202(1). 111–115. 2 indexed citations
8.
Yang, Jianmin, et al.. (2023). Phycocyanobilin from Arthrospira platensis: A potential photodynamic anticancer agent. Dyes and Pigments. 219. 111516–111516. 9 indexed citations
9.
Niu, Qi, Xin Qu, Shiyu Li, et al.. (2023). Hierarchical Fluid Interface Enables Spatiotemporal Regulation of Ligand Distribution to Increase Kinetics and Thermodynamics of Interfacial Binding Reaction. Angewandte Chemie International Edition. 62(49). e202312581–e202312581. 2 indexed citations
10.
Song, Zhiqiang, Gusheng Tang, Chunlin Zhuang, et al.. (2022). Metabolomic profiling of cerebrospinal fluid reveals an early diagnostic model for central nervous system involvement in acute lymphoblastic leukaemia. British Journal of Haematology. 198(6). 994–1010. 6 indexed citations
11.
Ma, Jiao, Bin Liu, Dan Yu, et al.. (2019). SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation. British Journal of Haematology. 187(1). 49–64. 49 indexed citations
12.
Wang, Ziwei, Weiping Zhang, Wei Tang, et al.. (2019). The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation. Annals of Hematology. 98(7). 1765–1773. 7 indexed citations
13.
Zhang, Ying, Yimin Zhang, Qi Chen, et al.. (2019). Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years. Annals of Hematology. 98(4). 997–1007. 17 indexed citations
14.
Zhang, Yimin, Haihui Gu, Qi Chen, et al.. (2019). Low Platelet Counts at Diagnosis Predict Better Survival for Patients with Intermediate-Risk Acute Myeloid Leukemia. Acta Haematologica. 143(1). 9–18. 18 indexed citations
15.
Shi, Yuankai, Q. Zhang, Xiao-Feng Han, et al.. (2018). First china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics). Annals of Oncology. 29. ix88–ix88. 3 indexed citations
16.
Qiu, Huiying, Shenglan Gong, Lili Xu, et al.. (2018). MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade. International Immunopharmacology. 64. 394–400. 9 indexed citations
17.
Li, Lili, Jianmin Wang, Weiping Zhang, et al.. (2011). Value of circulating galactomannan screening for early diagnosis of invasive aspergillosis in hematological patients. 20(7). 418–421. 1 indexed citations
18.
Lu, Sangwei, Jianmin Yang, Li Chen, et al.. (2009). The effects of proteasome inhibitor bortezomib on a P‐gp positive leukemia cell line K562/A02. International Journal of Laboratory Hematology. 32(1p1). e123–31. 19 indexed citations
19.
Zhao, Deming, Hongxiang Liu, Jianmin Yang, et al.. (2005). Altered Expression of the Prion Gene in Rat Astrocyte and Neuron Cultures Treated with Prion Peptide 106–126. Cellular and Molecular Neurobiology. 25(8). 1171–1183. 11 indexed citations
20.
Yang, Jianmin, Michael S. Friedman, Huimin Bian, et al.. (2002). Highly efficient genetic transduction of primary human synoviocytes with concentrated retroviral supernatant. Arthritis Research & Therapy. 4(3). 215–9. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026